Splanchnic vein thrombosis in necrotizing pancreatitis: a post-hoc analysis of a nationwide prospective cohort

HPB (Oxford). 2024 Apr;26(4):548-557. doi: 10.1016/j.hpb.2024.01.011. Epub 2024 Jan 29.

Abstract

Background: Treatment guidelines for splanchnic vein thrombosis in necrotizing pancreatitis are lacking due to insufficient data on the full clinical spectrum.

Methods: We performed a post-hoc analysis of a nationwide prospective necrotizing pancreatitis cohort. Multivariable analyses were used to identify risk factors and compare the clinical course of patients with and without SVT.

Results: SVT was detected in 97 of the 432 included patients (22%) (median onset: 4 days). Risk factors were left, central, or subtotal necrosis (OR 28.52; 95% CI 20.11-40.45), right or diffuse necrosis (OR 5.76; 95% CI 3.89-8.51), and younger age (OR 0.94; 95% CI 0.90-0.97). Patients with SVT had higher rates of bleeding (n = 10,11%) and bowel ischemia (n = 4,4%) compared to patients without SVT (n = 14,4% and n = 2,0.6%; OR 3.24; 95% CI 1.27-8.23 and OR 7.29; 95% CI 1.31-40.4, respectively), and were independently associated with ICU admission (adjusted OR 2.53; 95% CI 1.37-4.68). Spontaneous recanalization occurred in 62% of patients (n = 40/71). Radiological and clinical outcomes did not differ between patients treated with and without anticoagulants.

Discussion: SVT is a common and early complication of necrotizing pancreatitis, associated with parenchymal necrosis and younger age. SVT is associated with increased complications and a worse clinical course, whereas anticoagulant use does not appear to affect outcomes.

MeSH terms

  • Anticoagulants / therapeutic use
  • Disease Progression
  • Humans
  • Necrosis / complications
  • Necrosis / drug therapy
  • Pancreatitis, Acute Necrotizing* / diagnosis
  • Pancreatitis, Acute Necrotizing* / diagnostic imaging
  • Prospective Studies
  • Splanchnic Circulation
  • Venous Thrombosis* / diagnostic imaging
  • Venous Thrombosis* / epidemiology
  • Venous Thrombosis* / etiology

Substances

  • Anticoagulants